



## Press Release

Paris, 09 January 2015

### **KURMA Partners invests in Orphazyme ApS, a leading European biopharmaceutical company developing Heat Shock Protein based treatment for lysosomal storage diseases and other rare neurodegenerative diseases**

Kurma Partners, a key European player in the financing of Innovation in Healthcare, announces the 4th investment of its fund Kurma Biofund II, the first Venture Capital fund dedicated to financing innovation in the rare diseases space, in Orphazyme, a private Danish biopharmaceutical company developing a new class of small molecule against Lysosomal Storage Diseases. Orphazyme has raised 20 million euros in a Series B financing, led by Kurma Partners, Paris (Kurma), alongside Idinvest Partners, Paris, and current shareholders of Orphazyme. The company develops novel therapeutics for the treatment of rare and genetic diseases. The company was founded on pioneering research on the therapeutic potential of the cellular heat shock response and is now developing a family of well-tolerated small molecule inducers of heat shock proteins as treatments for lysosomal storage diseases and other neurodegenerative diseases. A clinical Phase 2 study in Niemann-Pick Disease type C, a detrimental lysosomal storage disease, is currently in preparation.

[A pdf version of Orphazyme press release can be found here.](#)

**A propos de KURMA Partners** - [www.kurmapartners.com](http://www.kurmapartners.com)

KURMA Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I and II, and strategic partnerships with prestigious European research and medical institutions.

#### **Press contacts**

**NewCap.** - Nicolas Merigeau : +33(0)1 44 71 94 98 - [nmerigeau@newcap.fr](mailto:nmerigeau@newcap.fr)